EUVIMEDEUVIMED entdecken
Kohortenstudie

Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study

Wan-Ming Chen, Ying-Hui Yu, Mingchih Chen, Ben-Chang Shia, Szu-Yuan Wu

Journal of Thoracic Oncology · 2023

DOI: 10.1016/j.jtho.2023.04.005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thoracic Oncology, 2023. Verfasst von Wan-Ming Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan; Artificial Intelligence Development…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: To determine the effect of statin use during concurrent chemoradiotherapy (CCRT) on overall survival and esophageal squamous cell carcinoma (ESCC)-specific survival in patients with ESCC receiving standard CCRT. METHODS: In this propensity score-matching cohort study, we used data from the Taiwan Cancer Registry Database and National Health Insurance Research Database to investigate the effects of statin use during the period of CCRT on overall survival and ESCC-specific survival. RESULTS: Statin use during the period of CCRT was found to be a considerable and independent prognostic factor for overall survival and ESCC-specific survival. The adjusted hazard ratio (aHR) for all-cause mortality in the statin group compared with that of the non-statin group was 0.65 (95% confidence interval: 0.51-0.84, p = 0.0009). The aHR for ESCC-specific mortality in the statin group compared with that of the non-statin group was 0.63 (95% confidence interval: 0.47-0.84, p = 0.0016). The use of hydrophilic statins such as rosuvastatin and pravastatin was associated with the greatest survival benefits. A dose-response relationship was also found, with higher cumulative defined daily doses and higher daily intensity of statin use associated with lower mortality. CONCLUSIONS: This study is the first to reveal that statin use during the period of CCRT for ESCC is associated with improvement in overall survival and ESCC-specific survival. In addition, we found that use of rosuvastatin, pravastatin, and simvastatin was associated with better survival outcomes for patients with ESCC receiving CCRT. Furthermore, we found a dose-response relationship of statin use associated with lower ESCC-specific mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaCarcinoma, Squamous CellEsophageal NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsHumansCohort StudiesPropensity ScoreRosuvastatin CalciumPravastatinChemoradiotherapy

Stichwörter der Autor:innen

Concurrent chemoradiotherapyDose-response relationshipEsophageal squamous cell carcinomaStatinSurvival

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumPravastatin

Autor:innen und Institutionen

  • Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan.
  • Department of Colorectal Surgery, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
  • Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan; Department of Foo…

Zitieren

APA

Chen, W. M., Yu, Y. H., Chen, M., Shia, B. C., & Wu, S. Y. (2023). Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2023.04.005

Vancouver

Chen WM, Yu YH, Chen M, Shia BC, Wu SY. Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study. Journal of Thoracic Oncology. 2023. doi:10.1016/j.jtho.2023.04.005

BibTeX
@article{Chen2023,
  author = {Chen, Wan-Ming and Yu, Ying-Hui and Chen, Mingchih and Shia, Ben-Chang and Wu, Szu-Yuan},
  title = {Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study},
  journal = {Journal of Thoracic Oncology},
  year = {2023},
  doi = {10.1016/j.jtho.2023.04.005}
}
Kostenlos starten →